Gadolinium-enhanced MRI is a sensitive and objective means to monitor disease activity in multiple sclerosis (MS). We evaluated the interobserver agreement and the value of observer training in reporting enhancing lesions from serial MRI. Scans of 16 MS patients were evaluated by five inexperienced and five experienced observers before and after consensus formation and training. The number of lesions at baseline, and the number of new and persistent lesions at follow-up were scored. For each condition, weighted kappa values ([kappa]) and the mean average difference to the median (MADM) scores were calculated. Without training, the Page 1 of 11 Ovid: Barkhof: Neurology, Volume 49(6). December 1997December .1682December -1688 1/23/2003 http://80-gateway2.ovid.com.ezproxy.lib.ucalgary.ca:2048/ovidweb.cgi experienced readers showed good agreement on number of lesions at baseline and new lesions at follow-up, and moderate agreement for persistent lesions. The inexperienced readers showed poor agreement for baseline and persistent lesions, and moderate agreement for new lesions. After training, both groups reported lower absolute numbers of lesions, especially the inexperienced readers. The experienced readers showed good agreement for all lesion types, the inexperienced readers showed agreement for baseline and new lesions, and agreement was moderate for persistent lesions. In both groups MADM scores were <0.72 for baseline and new lesions, but >1.2 for persistent lesions. Interobserver agreement is improved by training, especially in inexperienced readers. Interobserver agreement in reporting gadolinium-enhanced lesions is high, which validates the use of serial, enhanced MRI as an outcome parameter in treatment trials in MS.
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Article abstract
Gadolinium-enhanced MRI is a sensitive and objective means to monitor disease activity in multiple sclerosis (MS). We evaluated the interobserver agreement and the value of observer training in reporting enhancing lesions from serial MRI. Scans of 16 MS patients were evaluated by five inexperienced and five experienced observers before and after consensus formation and training. The number of lesions at baseline, and the number of new and persistent lesions at follow-up were scored. For each condition, weighted kappa values ([kappa] ) and the mean average difference to the median (MADM) scores were calculated. Without training, the experienced readers showed good agreement on number of lesions at baseline and new lesions at follow-up, and moderate agreement for persistent lesions. The inexperienced readers showed poor agreement for baseline and persistent lesions, and moderate agreement for new lesions. After training, both groups reported lower absolute numbers of lesions, especially the inexperienced readers. The experienced readers showed good agreement for all lesion types, the inexperienced readers showed agreement for baseline and new lesions, and agreement was moderate for persistent lesions. In both groups MADM scores were <0.72 for baseline and new lesions, but >1.2 for persistent lesions. Interobserver agreement is improved by training, especially in inexperienced readers. Interobserver agreement in reporting gadolinium-enhanced lesions is high, which validates the use of serial, enhanced MRI as an outcome parameter in treatment trials in MS.
Serial MRI frequently detects subclinical activity in multiple sclerosis(MS) patients. Given the high sensitivity of MRI and the objective nature of the information gathered, MRI is now frequently used to monitor treatment effect in clinical trials.1 Changes in T2 lesion load are used as a secondary outcome to assess disease progression over yearly intervals in definitive (phase III) trials, with changes in quantified volume of abnormal signal serving as the outcome parameter. In exploratory trials(early phase II), monthly MRI serves as the primary outcome measure, for which the accumulated number of active lesions is the outcome parameter.
Active lesions can be defined as any lesion that shows new or persistent enhancement, or any new or enlarging lesion on T2-weighted images without enhancement. With monthly MRI the majority of active lesions is detected by virtue of gadolinium enhancement, whereas the T2-weighted images add an extra 15% of active lesions.2 For the design of treatment trials and the power of such trials two issues are crucial-detection of enhancement and reporting enhancement.3 With regard to the former, the sensitivity of gadolinium-enhanced MRI can be increased by using a triple dose of gadolinium,4 magnetization transfer contrast,5 or delayed scanning.6 With regard to the latter, little information is available about the interobserver variation in reporting gadolinium enhancement.3
Detection of enhancement can either be computer assisted (quantitatively) or by visual inspection (qualitatively). Visual analysis of gadolinium-enhanced scans is a commonly employed strategy in the analysis of natural history and phase II treatment trials.7,8 Depending on the sort of quantitative technique used, computer-assisted techniques usually require human input at some stage. Human input can be very obvious, as in manual outlining or local thresholding techniques, but even so-called "automated" techniques frequently require operator review to remove spurious lesions.9 Therefore, even when quantitative techniques are used, it is important that the human operator is precise. Any interobserver-dependent variation can be regarded as noise and will reduce the power of treatment trials. We therefore undertook the present study to assess interobserver variation in visually reporting gadolinium-enhanced MS lesion on monthly MRI.
Methods. This study was carried out by two groups of five observers. The first group consisted of five research fellows (JHvW, GLàN, PM, NT, and MR) with limited experience in the interpretation of serial MR images, and who had only recently started working with MRI. More specifically we considered them to be inexperienced in that they had never systematically evaluated serial MR images in a scientific project. The second group consisted of five readers (FB, MF, DHM, EWR, and TY) who have ample experience with MRI in MS. We considered them to beexperienced because they had been involved in the systematic evaluation of serial MR images of MS patients, and most of the readers had been working together on scientific projects involving analysis of large series of serial MR images.
We used 16 pairs of scans consisting of previously acquired gadolinium-enhanced MR scans. They consisted of consecutive, monthly MR images from a recently completed trial of chimeric anti-CD4 antibodies, which was found to be ineffective. 8 The study design and full imaging protocol have been described in detail elsewhere.10 Briefly, the imaging protocol consisted of contiguous, axial, 5-mm slices with a 1-mm in-plane resolution, including T2-weighted fast spin-echo (FSE) (3,000/20, 100/1; TR/TE/excitations) and T1-weighted spin-echo (640/14/2) after gadolinium (0.1 mmol/kg). Repositioning between images was secured by the use of pilot scans in two planes and the use of internal landmarks. All images had been read initially by two experienced readers for treatment efficacy 8 and the results of this analysis were available in a trial database. From this database, four-by-four patients were randomly selected (HJA), stratified for having zero to one, two to five, six to 10, or more than 10 active (new or enlarging) lesions. All the images were hard copied again to ensure homogeneous image quality. Since lesions can only be active in comparison with a previous scan, for each patient there was a baseline scan and a follow-up scan. Even though the original readings in the database were established by two experienced readers by consensus, they were not considered to be a gold standard and were therefore not used further.
During the first reading session the observers independently read the images without any specific training or consensus formation. They analyzed the MR images for the number of enhancing lesions on the baseline scan, and the number of persistently enhancing and new enhancing lesions on the follow-up scan. Throughout this paper such lesions are referred to asbaseline, new, and persistent, respectively. Following this independent reading the observers compared their readings directly and tried to identify sources of disagreement to formulate rules to define enhancing lesions. This was done with the expectation that by formulating explicit definitions, interobserver variability would be reduced during the second reading. During a second reading session 3 months later, the observers independently read the same images again, applying the consensus rules developed after the first reading session. The information of the consensus readings was used to formulate guidelines to define gadolinium-enhanced lesions. The actual level of error in the readings was characterized by calculating the mean average difference to the median(MADM). Per parameter, the MADM was derived as follows. First, for each patient, the median of the observer scores was determined. Then each observer score was compared with the median and the absolute differences for all observers added, and divided by five. The MADM scores were compared between conditions using Wilconxon's matched-pairs signed rank test. To test for any systematic drift within the groups of observers over time, and between the groups of readers, we used Wilcoxon's matched-pairs signed rank test to compare the raw scores. To compare the two groups of observers further with regard to the effect of training, we performed ANOVA using deviation scores that were calculated by standardizing each score to the corresponding median score for that patient. A p value of less than 0.05 was considered to be statistically significant, and p values between 0.5 and 0.1 were considered to be trends.
Results. First reading session.
The experienced raters showed good agreement for number of baseline and new lesions, and moderate agreement for number of persistently enhancing lesions. The difference in [kappa] between new and persistent lesions was statistically significant (p = 0.02). The inexperienced readers showed lower[kappa]-scores than the experienced readers for each of the three conditions. Their level of agreement was poor for baseline and persistent lesions, and moderate for new lesions. This difference between the two groups was statistically significant for number of lesions at baseline, and showed a trend for new lesions (table 1) . The median lesion scores were lower for the experienced readers than for the inexperienced readers for baseline, new, and persistent lesions. This difference was significant for baseline (p < 0.001) and persistent lesions(p = 0.02). Also, the MADM was markedly higher for the inexperienced than for the experienced readers (p = 0.03 for baseline lesions). The experienced readers had an MADM for baseline and new lesions at follow-up of less than 0.8 lesions, whereas the inexperienced readers had an MADM of 1.17 or more (table 2) . Table 1 Weighted kappa scores (SD) Table 2 Median raw scores and mean average to the median(MADM) scores Consensus reading and guidelines. Direct comparison of the reading results by all readers after the first reading session revealed that many instances of disagreement occurred because of misclassification, and not because areas with increased signal were not identified as such. This was true especially in the experienced group. Misclassifications were related to(1) deciding whether enhanced areas seen in close proximity (either on the same slice or on adjacent slices) represented one single lesion or two separate lesions and (2) separating out new and persistent lesions (figures 1 and 2). Both types of classification errors tended to be influenced by the accuracy of repositioning the slices between examinations. Because of the errors in misclassification, it was decided to record first during the second reading session the number of areas of enhancement, without considering whether they were related to areas on contiguous slices, or whether they were new or persistent. . The baseline images show multiple, high-signal lesions, three of which enhance with gadolinium. The right frontal lesion shows a rimlike enhancement, which is accompanied by a continuous T2 abnormality, and therefore considered as one lesion. In total, six areas of enhancement are seen, which constitute only three lesions, all extending over two slices. At follow-up the ringlike lesion persists to enhance, while two new areas of enhancement have occurred (arrows). Their size is relatively small, but both are larger than 1 pixel and show a markedly increased signal. Importantly, they are accompanied by new abnormalities on the corresponding T2-weighted image (arrows). . At baseline a right frontal ring enhanced lesion is seen. Note that the two left frontal lesions have a marginally higher signal. This is at least partly contributed to the Mach effect (overshoot due to retinal processing), and these lesions are not considered to be enhancing. At follow-up there is no persistent enhancement, whereas a new area of enhancement has occurred along the left lateral ventricle (arrow). This lesion is easily differentiated from an enhancing vessel by the coexistence of a new T2 abnormality (arrow).
Another major source of variation was the definition of what constituted an enhanced lesion. The results of the consensus readings of the inexperienced and experienced readers were quite similar, and have been merged to serve as an overall consensus about the definition of gadolinium-enhanced lesions. Generally speaking, both groups of readers felt that to achieve agreement, some sort of conservatism was necessary to avoid overreading. Preferably, areas of enhancement should not be too small, should have a markedly enhanced signal, and should be accompanied by an increased signal on the corresponding T2-weighted image (see figures 1 and 2). Specific considerations were formulated for new and persistent lesions, homogeneous and ring enhancing lesions, and for certain anatomic areas. The complete consensus guidelines and illustrative examples are presented in the Appendix and figures 1 and 2, respectively.
Second reading session. The [kappa]-scores for every type of lesion were higher than the [kappa]-scores during the first reading session. Good agreement was exhibited for all lesion types in the experienced group, and for all but persisting lesions in the inexperienced group (see table 1 ). The improvement was most marked, however, in the inexperienced group, which now showed a level of agreement that was comparable with the experienced readers (p > 0.2 for all comparisons). The improvement in the level of agreement between the two reading sessions was significant for baseline lesions (p = 0.04) and showed a trend for persistent lesions (p = 0.09) for the inexperienced readers (see table 1 ). For the follow-up scans, interobserver agreement was excellent for the number of areas, with a[kappa]-score of 0.84, higher than for any type of lesion on those scans.
The median lesion scores were lower for both groups of readers during the second reading (p < 0.01 for all comparisons). The inexperienced readers now showed similar average scores as the experienced readers(p > 0.09 for baseline, new, and persistent lesions), which means they were much more conservative than during the first reading session. The reduction of the MADM scores in the presence of lower median scores in both groups indicates that the number of misclassifications was markedly reduced (see table 2 ). For the inexperienced group the decrease in MADM was significant for baseline (p = 0.002) and new (p = 0.004), but not for persistent lesions(p = 0.88). For the experienced readers the decrease in MADM was less pronounced (p > 0.15 for all lesion types).
Analysis of variance showed differences between groups (F = 27.02, p = 0.0001), session (F = 65.79, p< 0.00001), and type of lesions (F = 13.82, p = 0.0001), confirming that experienced readers performed better than inexperienced readers, training and consensus formation improved agreement, and that these effects were more marked for baseline and new lesions than for persistent lesions. It further revealed significant interactions between group and session (F = 9.57, p = 0.007), and between session and type of lesion (F = 32.09, p < 0.00001). This confirms that inexperienced readers improved more than experienced readers, and that training and consensus formation had more effect on baseline and new lesions than on persistent lesions. Further interactions were observed between readers and occasion (F = 7.09, p< 0.00001), and between readers and type of lesion (F = 2.38,p = 0.003), illustrating that the aforementioned effects of training and types of lesions were different between readers.
Discussion. The growing use of MRI as a marker of disease activity in MS is based on the assumptions that MR is more sensitive than clinical evaluation for the underlying disease process, provides a retrievable document, facilitates blinding, and is more reproducible.3 This paper deals with the latter assumption, one that is sometimes put forward when limitations of clinical scoring methods are considered. Initial reports indicate that the level of agreement on recording the number of gadolinium lesions may be quite reasonable,3 but so far this issue has not been addressed systematically.
Our study shows that experienced observers are more conservative than inexperienced observers, and show good agreement without training. Their average error in reporting a number of gadolinium lesions (MADM) is less than one lesion per scan in most cases. By contrast, without training, inexperienced readers show poor to moderate agreement. Their MADM was more than one lesion for any type of lesion. The level of agreement improved after training and consensus formation, although this effect was most pronounced in the inexperienced group. During the second reading session, average lesion scores were comparable in both groups, as were the MADM scores. The inexperienced readers now showed good agreement for most types of lesions (except for persistent lesions) and were comparable with the experienced readers (see table 2 ).
One could argue that higher [kappa]-values are simply the result of too much conservatism. Both the weighted [kappa]-scores and the MADM take into account that the absolute differences between readers tend to increase as the median scores increase. The fact that both measures improve in the presence of lower median scores indicates that differences between readers were more strongly reduced than their average scores, and that the improved agreement is not simply the effect of underreporting. Of course, there is a tension between precision and accuracy here. With consistent low scores (in the most extreme case a score of zero in all patients), one may be more precise, while at the same time losing sensitivity. Alternatively, if one tries to increase sensitivity by reporting even the most subtle abnormality, precision gets worse. Using more sophisticated techniques it has been shown that detection of gadolinium enhancement can be markedly improved,4-6,13 which illustrates that accuracy is a relative quantity for which no gold standard exists. Precision, for that matter, is much better defined and, to a certain degree, is more important if one aims to compare subgroups of patients, especially in the setting of treatment trials.
The guidelines formulated based on the consensus readings in this study reflect a slight tendency for conservatism. Ideally each area of enhancement is accompanied by a (new) area of increased signal on the corresponding T2-weighted image. The type of lesion where this rule fails by definition is that of persistent enhancement, where a persistent T2 abnormality is almost invariably present, but where the reader is also biased by the knowledge of having observed enhancement in that particular area previously. To avoid this bias one could consider reading the images in reverse order, starting with the last set of scans. There are three reasons for which one could argue that persistent lesions should be disregarded, specifically in the setting of treatment trials. First, the number of persistent lesions is low in comparison with the number of new lesions. Second, reproducibility of reporting such lesions is almost twice as poor as for new lesions. Third, persistent lesions are of lesser importance than new lesions if one is monitoring the pathologic process in MS patients. This latter hypothesis remains speculative, however.
The strategy of simply recording the number of abnormal areas proved to be quite reproducible, especially for follow-up scans, which are more complex to analyze than baseline scans because a comparison with previous scans has to be performed. Reporting only abnormal areas obviates two further processes-deciding whether two areas on consecutive slices represent one or two lesions, and whether this lesion is new or persisting. Its simplicity is attractive, and the result probably more comparable with the alternative of visual reporting (i.e., quantitative lesion load measurement). This might actually have been the most important reason for improvement in the experienced group. Reporting areas prior to detailing new and persistent lesions is also an administrative aid, because the process of identification of abnormalities is no longer intermingled with classification and, in addition, it is quicker.
Our study focused on detecting enhancing MS lesions using monthly scans. For this scanning interval, gadolinium enhancement is the most sensitive technique to detect new activity,2 and therefore is frequently used in phase II treatment trials.1 Using a lower sampling rate (i.e., longer intervals), the sensitivity of gadolinium enhancement will decrease, and detection of activity now depends on the comparison of serial T2-weighted images. This can again be done either by visual inspection (compare consecutive scans to detect new abnormalities) or computer-assisted inspection (subtract quantitative lesion loads between consecutive observations). The exact technique to be used and the related level of agreement between observers is still a matter of debate.9 Phase III treatment trials frequently rely on T2 lesion load assessment, although the use of gadolinium enhancement is probably underestimated. Given the large sample sizes in such studies, a"snapshot" cross-sectional comparison can be performed based on analysis of the percentage of patients showing enhancement.14 Our reproducibility data on the number of baseline lesions supports the validity of this strategy.
The efficacy of using gadolinium enhancement to monitor disease activity in MS is influenced by the sensitivity in detecting and thereproducibility in reporting enhancing lesions.3 Our study focused on the latter, and showed that interobserver agreement is substantial among observers. While intraobserver agreement was not studied, with good interobserver agreement it follows that intraobserver agreement must be at least as good. Consensus formation and training are essential, especially when the experience of the observers is limited. The consensus guidelines formulated during this process (see the Appendix, page 1688) can be used to train new observers. Reporting areas instead of lesions may be quite useful and facilitates the distinction between new and persistent lesions, even though reproductibility of the latter remains questionable.
the conspicuity of enhancing lesions on T2-weighted images. T2 confirmation can be difficult in areas where contrast is suboptimal, especially in the cortical area (with a higher signal in the cortex than in the white matter, and therefore a lower contrast between lesions and background).
A new enhancing lesion is defined as an area of enhancement in an place that showed no enhancement on a previous scan (see figure 1) . Most convincing is a new T2 abnormality on serial scans, but reenhancement can of course occur in a preexisting T2 lesion, although it is considered less persuasive. Apersistently enhancing lesion is defined as area of enhancement in a place that did show enhancement on a previous scan (see figure 1) . Usually Usually the accompanying T2 abnormality persists, but can change in size (e.g., enlarge).
Low levels of enhancement can be difficult to interpret. Care should be taken to avoid too small a window in preparing the hard copies. In the vicinity of lesions that are hypointense on T1-weighted SE images, enhancement might be falsely suggested. The suggestion of a high signal around hypointensity can be introduced by what is called the Mach effect (see figure 2 ).
With the knowledge that an enhancing lesion was seen in a particular area on a previous scan, it can sometimes be difficult to decide whether very slight persistent enhancement is still present in that location at follow-up. One should essentially use the same criteria as for new lesions: Would you identify it as a new enhancement? Because MS lesions frequently arise in close proximity, differentiating new from persistent enhancements can be difficult, especially when the repositioning of the imaging slices is not optimal. One can try to measure the distance from the midline or superimpose the images (when the images have the same zoom factor). As an alternative, one could try not to separate new and persistent lesions, but simply to register all areas of enhancement as activity.
Even using these definitions, there are many circumstances that will interfere with the interpretation of enhancing lesions:
1. MS lesions are frequently seen around the ventricles, but care should be taken not to include subependymal veins. These structures differ from MS lesions in that they are longitudinal, thin, and frequently show signal void on T2-weighted images. Likewise, in the basal ganglia, Virchow-Robin spaces with enhancing vessels should be ruled out. 2. The thickness of the imaging slices is usually 5 mm, which allows partial volume averaging between brain tissue and other structures, such as the choroid plexus. Erroneous interpretation of the choroid plexus is most likely to occur at the level of the trigone of the lateral ventricle. To avoid confusion with the choroid plexus in adjacent slices, preferably one normal slice in between an area of enhancement and the choroid plexus should be present. 3. Flow-related artifacts become more conspicuous after gadolinium injection and are particularly troublesome in the posterior fossa. In this area T2-weighted images should always be abnormal. This is of course at the risk of either a false-positive decision because of a preexisting T2 abnormality or a false-negative in the case of no T2 abnormality, yet. 4. Brainstem lesions can be small and difficult to recognize. The brainstem should be scrutinized separately, and even very small lesions should be considered when the T2-weighted image is abnormal. The medulla oblongata is even more difficult. There should be no flow artifacts, and a definite T2 abnormality is mandatory. In addition, the area of enhancement should either be very clearly demarcated or surrounded by a clear rim of normal brainstem tissue. 5. In the case of enhancement in the cortical/subcortical area, it might be difficult to confirm the presence of a lesion on T2-weighted images with conventional SE imaging. Enhancement should be seen ideally only if visible on two consecutive slices. Specifically, if a sulcus is present on the slice immediately above or below, the abnormality should be disregarded if it is very small and only seen on one slice. 6. Special care should be paid to the basal frontal area, where false-positive abnormalities can be induced by the sinuses due to either susceptibility effects at the interface with aerated sinuses or due to partial volume
